多西他赛联合雷替曲塞治疗晚期胃癌的效果观察

Efficacy of docetaxel combined with raltitrexed in the treatment ofpatients with advanced gastric cancer

目的:探讨多西他赛联合雷替曲塞治疗晚期胃癌的效果。方法:选取60例晚期胃癌患者,按照随机数字表法分为对照组和实验组,每组各30例。对照组采用多西他赛治疗,实验组采用多西他赛联合雷替曲塞治疗,治疗3个疗程后,比较两组患者的临床疗效、肿瘤标志物水平变化、胃癌患者生命质量问卷(QLQ STO-22)量表评分以及不良反应发生率。结果:实验组总有效率高于对照组(P<0.05);治疗后,实验组患者肿瘤标志物癌胚抗原(CEA)、糖类抗原199(CA199)水平均低于对照组(P<0.05);治疗后,实验组QLQ STO-22量表评分明显低于对照组,两组比较差异有统计学意义(P<0.05);两组不良反应比较差异无统计学意义(P>0.05)。结论:多西他赛联合雷替曲塞治疗晚期胃癌安全有效,能够有效降低血清肿瘤标志物水平,改善患者生命质量。

Objective: To investigate the efficacy of docetaxel combined with raltitrexed in the treatment of patients with advanced gastric cancer. Methods: 60 patients with advanced gastric cancer were randomized into the control group and experimental group, each with 30 cases. The control group were treated with docetaxel alone, while the experimental grouup were treated with docetaxel combined with raltitrexed. After three courses of treatment, the efficacy, changes of tumor markers, scores of quality of life questionnaire for gastric cancer patients(QLQ STO-22)and incidence of adverse reactions were compared between the two groups. Results: The total effective rate of the experimental group was higher than that of the control group(P<0.05);and the levels of tumor markers CEA and CA19-9 in the experimental group were lower than those in the controlgroup after treatment, the difference between the two groups was statistically significant(P<0.05);the score of STO-22 was significantly lower than that of the control group, which was of statistical significance(P<0.05);and there was no statistical difference in the incidence of adverse reactions between both groups(P>0.05). Conclusion. Docetaxel combined with raltitrexed is safe and effective in the treatment of patients with advanced gastric cancer, which can effectively reduce the level of serum tumor markers and improve the quality of life of patients.